Back to Search
Start Over
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience
- Source :
- Leukemia & Lymphoma. 62:419-427
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (
- Subjects :
- Adult
Oncology
Cancer Research
medicine.medical_specialty
Transplantation Conditioning
Graft vs Host Disease
ThioTEPA
Single Center
03 medical and health sciences
0302 clinical medicine
Internal medicine
Humans
Medicine
Myelofibrosis
Busulfan
Aged
business.industry
Hematopoietic Stem Cell Transplantation
Hematology
Middle Aged
medicine.disease
Fludarabine
Transplantation
Haematopoiesis
Primary Myelofibrosis
030220 oncology & carcinogenesis
Cohort
business
Thiotepa
Vidarabine
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 10292403 and 10428194
- Volume :
- 62
- Database :
- OpenAIRE
- Journal :
- Leukemia & Lymphoma
- Accession number :
- edsair.doi.dedup.....df512b84a986c793d3ae42bbeb36d85f